OR WAIT null SECS
Nanoform has unveiled its plans to construct a GMP manufacturing plant that will provide API ‘solution to particle’ nanoization for clinical trials
Nanoform, a drug enabling nanotechnology company, has unveiled its plans to construct a GMP manufacturing plant that will provide API ‘solution to particle’ nanoization for clinical trials in a Dec. 10, 2018 press release.
The new GMP-compliant plant will be located at Viikki Life Science Park in Helsinki, Finland, and will accommodate a six-fold growth in capacity. Enabling Nanoform to increase its potent API handling capacity, the facility will ensure the growth in demand for formulations with improved solubility and bioavailability can be met.
“We are very excited to announce the construction of our new GMP-compliant facility, a key milestone in our growth strategy,” said Christian Jones, CCO of Nanoform, in the release. “We believe we are the only company globally that can produce excipient-free nanoparticles below 200 nm directly from solution and at scale, whilst controlling their physico-chemical attributes. This offers significant advantage for our customers development molecules, enabling solutions to problematic compounds, transforming existing formulations and adding lifecycle protection to current pipeline drugs.”
Edward Hæggström, CEO of Nanoform, added, “Our revolutionary technology is set to double the number of drugs that make it to market each year. The GMP manufacturing facility exemplifies Nanoform’s rapid expansion as a company and our commitment to enhancing treatments for patients across the globe.”
This expansion in facilities has been possible through a EUR 7 million (approximately US$8 million) cross-border private placement funding from Vator Securities and Borenius.